ClinicalTrials.gg
RecruitingNCT07777484Updated Sep 10, 2026

An Unblinded, Single Arm, Pilot Observational Study to Test the Safety, Tolerability, Immunogenicity and the Biological Effects of TRB-001 Vaccination.

A Phase 1 interventional study of TRB-001 in Parkinson's Disease, sponsored by Tridem Bioscience FlexCo. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Tridem Bioscience FlexCo · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies in Parkinson Disease with a site in Austria — 10 open to participants now, 16 under way, 2 of them phase 3. Parkinson Disease · Austria.

Planned enrollment
71st of 71
6 · median 189
Started
2026
with 2 others
Phase 1
7 of 87
2 open now
Primary completion
2026-12
later than 8 of 15 live
Registered
85th of 87
by date

Among the 87 studies in Parkinson Disease with a site in Austria, this one is the 71st largest by planned enrollment of the 71 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 1, reaches primary completion later than 8 of the 15 other live ones, and was the 85th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

10 of the 87 studies in Parkinson Disease with a site in Austria are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Parkinson Disease with a site in Austria, or all of them as a file.
02

Study summary

An unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy

03

Conditions studied

  • Parkinson's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18-years of age
  • Female or male with previous treatment with active aSyn immunotherapy
  • Parkinson's disease diagnosis (any stage)
  • Understands and agrees to comply with the study procedures and provides written

Exclusion criteria

Exclusion Criteria:

  • Women of without use of
  • Women who are pregnant or lactating
  • for MRI or lumbar puncture
  • Known or suspected allergy, or history of anaphylaxis, to vaccines or their , if considered relevant by the investigator
  • Presence or history of disease or immunodeficiency, if considered relevant by the investigator
  • Presence of active infectious disease (, , or (HIV))
  • Significant cognitive impairment or clinical dementia, or a (MoCA) score \<26
  • High suspicion of other parkinsonian syndromes, such as multiple system atrophy, progressive supranuclear palsy, drug-induced Parkinsonism and post-encephalitic Parkinsonism
  • Any relevant systemic illness. This includes cardiovascular, hepatic, gastroenterological, respiratory, endocrinological, hematologic disease, or any other condition that, in the investigator's opinion, could interfere with the analyses of safety and efficacy in this study, unless patient has been on stable doses of medication for any of these concurrent illnesses for at least 3 months prior to study entry
  • Unstable psychiatric illness, including psychosis, suicidal ideation, untreated major depression, schizophrenia, or bipolar affective disorder within 90 days before Visit 1, as determined by the investigator
  • History of drug or alcohol abuse within the past 5 years
  • Recent history (≤2 years) of cancer (exceptions; basal cell carcinoma, intraepithelial cervical neoplasia)
  • Birthmarks, tattoos, wounds, or skin conditions that may obscure the assessment of injection site reactions
  • Participation in the active treatment phase of any non-PD clinical trial within 30 days prior to Visit 1
  • Dose limiting toxicity to previous immunization with aSyn-based PD vaccine
  • Current therapy
  • Employee at the study site, spouse/partner or relative of any study staff (e.g. investigator, sub-investigators, or study nurse) or relationship to sponsor
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Verum Arm

    Each participant will receive 1 immunization with Vaccine at week 0. Participants may also receive a 2nd immunization at week 4-6, pending safety and immunogenicity results and decision from PI, Sponsor, and Medical Monitor.

    Biological: TRB-001

Interventions

  • BiologicalTRB-001

    This is an unblinded, single arm, pilot observational study to test the safety, tolerability, immunogenicity and the biological effects of TRB-001 vaccination in individuals who have previously undergone aSyn immunotherapy. After the screening period, all participants who are enrolled in the study will receive a first intradermal TRB-001 immunization at a dose of 100μg. Patients antibody response will be assessed at week two (compared to baseline). Based on the safety and immunogenicity results, the PI, Medical Monitor, and Sponsor will decide on a potential second immunization with TRB-001. Regarding immunogenicity, a predefined cut-off will be used. The patient may be offered another injection to be applied 4-6 weeks after the first immunization with TRB-001. Participants will be evaluated at week 24. Assessments will include safety, immunogenicity, blood-/CS

06

What researchers measure

Primary outcomes

  1. Incidence of local and systemic treatment-emergent adverse events (TEAEs)

    Incidence of local and systemic treatment-emergent adverse events (TEAEs) (occurrence, intensity, duration, and relationship to IMP) over 6-months

    Time frame: 6 months

Secondary outcomes

  1. Titers of vaccine-induced antibodies in blood and CSF

    Titers of vaccine-induced antibodies (immunizing peptide, aSyn monomer; area under the curve for both parameters) in blood and CSF (peptide only) over 6 months compared to baseline

    Time frame: 6 months

  2. Change from baseline in total aSyn levels

    Change from baseline in total aSyn levels as assessed by ELISA in blood and CSF

    Time frame: 6 months

  3. Change in levels of aggregated aSyn in blood and CSF

    Change from baseline in levels of aggregated aSyn in blood and CSF

    Time frame: 6 months

  4. Change in GFAP and Neurofilament light chain in CSF

    Change from baseline in GFAP and Neurofilament light chain in CSF

    Time frame: 6 months

  5. Avidity of antibodies induced for aggregated aSyn

    Avidity of antibodies induced for aggregated aSyn as assessed after the vaccination with TRB-001 compared to baseline

    Time frame: 6 months

  6. Selectivity of antibodies induced by TRB-001

    Selectivity of antibodies induced by TRB-001 for aggregated aSyn

    Time frame: 6 months

  7. Change from baseline of the seed amplification assay signal (CSF)

    Change from baseline of the seed amplification assay signal (CSF)

    Time frame: 6 months

  8. Correlation between measures of the antibody response

    Correlation between measures of the antibody response (peptide titer, aSyn titer, avidity, titers x avidity, selectivity and biomarkers of the disease) (change from baseline in total aSyn levels, levels of aggregated aSyn in blood and CSF)

    Time frame: 6 months

  9. Change in MDS-UPDRS I, II, III, and IV

    Change from baseline in MDS-UPDRS I, II, III, IV

    Time frame: 6 months

  10. Change from baseline in PD symptoms

    Change from baseline in PD symptoms using the wearable device STAT-ON(TM)

    Time frame: 6 months

  11. Change in symptomatic PD medication

    Change from baseline in symptomatic PD medication (Levodopa equivalent dose)

    Time frame: 6 months

  12. Change in levels of circulating extracellular vesicle (EV)-based biomarkers

    Change from baseline in Levels of circulating extracellular vesicle (EV)-based biomarkers

    Time frame: 6 months

  13. Change in the number of vaccine specific B- and T cell clones

    Change from baseline in the number of vaccine specific B- and T cell clones as assessed by B/T cell receptor sequencing

    Time frame: 6 months

  14. Incidence of local and systemic TEAEs

    Incidence of local and systemic TEAEs over 12- months

    Time frame: 12 months

  15. Change from baseline in total aSyn levels

    Change from baseline in total aSyn levels as assessed by ELISA in blood

    Time frame: 12 months

  16. Change from baseline in levels of aggregated aSyn in blood

    Change from baseline in levels of aggregated aSyn in blood

    Time frame: 12 months

  17. Titers of vaccine-induced antibodies in blood

    Titers of vaccine-induced antibodies (immunizing peptide, aSyn monomer; area under the curve for both parameters) in blood

    Time frame: 12 months

  18. Change from baseline in MDS-UPDRS I, II, III, IV at 12 month time period

    Change from baseline in MDS-UPDRS I, II, III, IV

    Time frame: 12 months

  19. Change from baseline in PD symptoms at 12 month time period

    Change from baseline in PD symptoms using the wearable device STAT-ONTM

    Time frame: 12 months

  20. Change from baseline in symptomatic PD medication at 12 month time period

    Change from baseline in symptomatic PD medication (Levodopa equivalent dose) Change from baseline in the number of vaccine specific B- and T cell clones as assessed by B/T cell receptor sequencing

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • PROSENEX Study Centre at the ATOMOS Klinik Währing
    Vienna, 1180, Austria
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 5 months is below that.

Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 20, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jul 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07777484
Lead sponsor
Tridem Bioscience FlexCo
Responsible party
Sponsor
First posted
Aug 20, 2026
Start date
Jul 28, 2026
Primary completion
Dec 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Markus Mandler
Contact
markus.mandler@tridem.at
+43 699 11603817
Achim Schneeberger, Dr.
study director · Tridem Bioscience FlexCo

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion